EvaTIP: Assessment of the Impact of TIP Score on Thromboprophylaxis in Patients With Non-surgical Lower Leg Trauma.

Sponsor
University Hospital, Angers (Other)
Overall Status
Completed
CT.gov ID
NCT03089255
Collaborator
(none)
196
1
9.9
19.8

Study Details

Study Description

Brief Summary

Traumatic lesions are the leading causes of admission to the emergency center (39%), isolated non-surgical lower limbs trauma are in the foreground. Two recent meta-analyzes suggest the value of Low Molecular Weight Heparins (LMWH) which would reduce symptomatic Thromboembolism Events (TE) in patients with lower limb trauma. However, many recent studies conclude to the need of stratifying the TE risk according to the patient and the nature of his trauma to obtain an individualized therapeutic decision.

The retrospectively established L-TRIP (cast) score allows stratification of the risk without taking into account the type of trauma. The TIP score (Trauma, Immobilization and Patient) was established by consensus of international experts via the Delphi method.

We suggest that the application of the TIP score to rationalize indications of thromboprophylaxis in patients with isolated non-surgical trauma of a lower limb should reduce the rate of anticoagulation prescription without increasing the risk of symptomatic thromboembolic complications with a direct benefit for patients and medico-economic for the society.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    All patients admitted to the Emergency Departments for a nonsurgical isolated lower limb trauma necessitating rigid or semi-rigid immobilization, will be assessed for possible participation.

    After the physicians had obtained the no-opposition of the patient, they will fill a questionnaire. This questionnaire includes the treatment chosen by the physician, the type of trauma, the type of immobilization chosen, and the patient's thromboembolic risk factors in order to calculate the TIP and L-TRIP (cast) scores retrospectively.

    Phone follow-up will occur within 3 months to gather clinical event data (any signs of VTE, any bleeding events).

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    196 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Study to Assess the Foreseeable Impact of TIP Score on Thromboprophylaxis in Patients With Isolated Non-surgical Lower Limb Trauma Compared to the Physicians' Judgment in Standard Practice.
    Actual Study Start Date :
    Apr 3, 2017
    Actual Primary Completion Date :
    Jan 15, 2018
    Actual Study Completion Date :
    Jan 30, 2018

    Outcome Measures

    Primary Outcome Measures

    1. Rate of prescriptions of prophylactic anticoagulation if TIP score was applied compared to the physicians' judgment in standard practice. [one day]

      Compare two rate (percent) of prescription: obtained with standard practice and with the foreseeable TIP score calculated retrospectively. Score TIP is calculated retrospectively based on datas of the patients included. A threshold value is established by an expert consensus. A score is positive if it is higher than the threshold value, and negative if it is lower or equal to the threshold value. We consider that patients with a negative score would not have been treated by a prophylactic anticoagulation if the TIP score was applied.

    Secondary Outcome Measures

    1. Rate of prescriptions of prophylactic anticoagulation if L-TRIP(cast) score was applied compared to the physicians' judgment in standard practice. [one day]

      Compare two rate (percent) of prescription: obtained with standard practice and with the foreseeable L-TRIP(cast) score calculated retrospectively. A score is positive if it is higher than the threshold value, and negative if it is lower or equal to the threshold value. We consider that patients with a negative score would not have been treated by a prophylactic anticoagulation if the TIP score was applied.

    2. The cumulative rate of symptomatic venous thromboembolism (i.e. deep venous thrombosis and/or pulmonary embolism) at 3 months from inclusion. [3 months]

      The following definitions are applied to confirm a suspected episode of symptomatic : DVT: abnormal compression ultrasound PE: an intraluminal filling defect in segmental or more proximal branches on spiral CT Scan or a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan or detected at autopsy.

    3. The 3-month rate of major bleeding and of non-major clinically relevant bleeding according to the ISTH definition. [3 months]

      The safety endpoint is major bleeding, defined according to the recently published guidelines of the ISTH : Fatal bleed ing, and/or Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra- articular or pericardial, or intramuscular with compartment syndrome, and/or Bleeding causing a fall in hemoglobin level of 20 g.L (1.24 mmol.L) 1 or more, or leading to transfusion of two or more units of whole blood or red cells. The cumulative incidence of non-major clinically relevant bleeding. The cumulative incidence of minor bleeding.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Consultation in one of the emergency departments of the participating centres

    • Isolated unilateral lower limb injury not requiring surgery

    • Lower limb rigid or semi-rigid orthopedic immobilization (i.e. brace of plaster cast) for at least 5 days.

    • Full insurance cover

    Exclusion Criteria:
    • Any anticoagulant or antiplatelet treatment prior to trauma

    • Contra-indication to fondaparinux or LMWH

    • Factors rendering 3-month follow-up impossible

    • Imprisonment

    • Inability to provide informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Douillet Angers France 49000

    Sponsors and Collaborators

    • University Hospital, Angers

    Investigators

    • Principal Investigator: Roy Pierre-Marie, MD, PhD, University Hospital, Angers

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Angers
    ClinicalTrials.gov Identifier:
    NCT03089255
    Other Study ID Numbers:
    • 2017-A00291-52
    First Posted:
    Mar 24, 2017
    Last Update Posted:
    Jun 4, 2018
    Last Verified:
    Jun 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Angers
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 4, 2018